Sveobuhvatna analiza α i β-thalassemia genotipa i hematoloskih fenotipa
Analysis of thalassemia genotypes and hematologic phenotypes
Sažetak
Background: Guizhou Province is an area with high incidence of thalassemia. However, there are few large-sample studies on the correlation between genotypes and phenotypes in Guizhou Province. In this study, the phenotypes and genotypes of 1174 patients with thalassemia in Guizhou Province were collected, and the relationship between different genotypes and phenotypes was analyzed, providing a more accurate basis for genetic counseling, prevention and control of thalassemia.
Methods: A total of 1174 patients with thalassemia were collected in Guizhou Provincial People's Hospital from October 2020 to December 2021 by PCR-reverse dot blot (RDB) hybridization assay, and their red blood cell (RBC), hemoglobin (Hb), mean erythrocyte volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), hemoglobin (HbA), hemoglobin A2(HbA2), and fetal hemoglobin (HbF) data were collected. The relationship between different genotypes and phenotypes was analyzed.
Results: Among 1174 cases of thalassemia or carriers, there were 617 cases of α-thalassemia, 512 cases of β-thalassemia, 45 cases of coinheritance of α- and β-thalassemia. The severity of anemia between α-thalassemia was positively correlated with the decrease of non-functional copy number of α-globin gene. The degree of anemia in non-deletion α-thalassemia was greater than that in deletion α-thalassemia. In β-thalassemia, β0 gene mutation did not produce β-globin, and β+ mutation expressed some β-globin, but it was lower than normal level. β0/β0 had no β-globin production, and long-term blood transfusion was required to maintain life. Compared with α-thalassemia, the degree of anemia in β-thalassemia whose clinical type was same as α-thalassemia was more serious. The anemia degree of coinheritance of α- and β-thalassemia was less than that of simple α-thalassemia or β-thalassemia.
Conclusion: The clinical phenotype of thalassemia is influenced by molecular mechanism, and the two kinds of thalassemia can interact with each other. The clinical severity is positively correlated with the imbalance of α peptide chain and β peptide chain. A comprehensive understanding of the hematologic phenotype differences between different genotypes and subtypes of thalassemia can provide more accurate data for genetic counseling of thalassemia.
Reference
2. Weatherall DJ. The Evolving Spectrum of the Epidemiology of Thalassemia. Hematol Oncol Clin N 2018; 32(2): 165-75.
3. Mettananda S, Higgs DR. Molecular Basis and Genetic Modifiers of Thalassemia. Hematol Oncol Clin N 2018; 32(2): 177-91.
4. Huang SW, Xu Y, Liu XM, Zhou M, Li GF, An BQ, et al. The Prevalence and Spectrum of alpha-Thalassemia in Guizhou Province of South China. Hemoglobin 2015; 39(4): 260-3.
5. Kalle KI, Lai MI, Md NS. Non-deletional alpha thalassaemia: a review. Orphanet J Rare Dis 2020; 15(1): 166.
6. Huang SW, Liu XM, Li GF, Su L, Wu X, Wang RL. Spectrum of beta-thalassemia mutations in Guizhou Province, PR China, including first observation of codon 121 (GAA>TAA) in Chinese population. Clin Biochem 2013; 46(18): 1865-8.
7. Muncie HJ, Campbell J. Alpha and beta thalassemia. Am Fam Physician 2009; 80(4): 339-44.
8. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genom Med 2021; 9(12): e1788.
9. Thein SL. The molecular basis of beta-thalassemia. Csh Perspect Med 2013; 3(5): a011700.
10. Jiang F, Ju AP, Li J, Chen GL, Zhou JY, Tang XW, et al. Hb Westmead (HBA2: c.369C>G): Hematological Characteristics in Heterozygotes with and without alpha(0)-Thalassemia. Hemoglobin 2020; 44(3): 153-5.
11. Piel FB, Weatherall DJ. The alpha-thalassemias. New Engl J Med 2014; 371(20): 1908-16.
12. Shang X, Xu X. Update in the genetics of thalassemia: What clinicians need to know. Best Pract Res Cl Ob 2017; 39: 3-15.
13. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis 2010; 5: 13.
14. Liebhaber SA, Cash FE, Main DM. Compensatory increase in alpha 1-globin gene expression in individuals heterozygous for the alpha-thalassemia-2 deletion. J Clin Invest 1985; 76(3): 1057-64.
15. Wajcman H, Traeger-Synodinos J, Papassotiriou I, Giordano PC, Harteveld CL, Baudin-Creuza V, et al. Unstable and thalassemic alpha chain hemoglobin variants: a cause of Hb H disease and thalassemia intermedia. Hemoglobin 2008; 32(4): 327-49.
16. Sriiam S, Leecharoenkiat A, Lithanatudom P, Wannatung T, Svasti S, Fucharoen S, et al. Proteomic analysis of hemoglobin H-constant spring (Hb H-CS) erythroblasts. Blood Cell Mol Dis 2012; 48(2): 77-85.
17. Thein SL. Molecular basis of beta thalassemia and potential therapeutic targets. Blood Cell Mol Dis 2018; 70: 54-65.
18. Bou-Fakhredin R, Motta I, Cappellini MD. Advancing the care of beta-thalassaemia patients with novel therapies. Blood Transfus-Italy 2022; 20(1): 78-88.
19. Han WP, Huang L, Li YY, Han YY, Li D, An BQ, et al. Reference intervals for HbA(2) and HbF and cut-off value of HbA(2) for beta-thalassemia carrier screening in a Guizhou population of reproductive age. Clin Biochem 2019; 65: 24-8.
20. Lohani N, Bhargava N, Munshi A, Ramalingam S. Pharmacological and molecular approaches for the treatment of beta-hemoglobin disorders. J Cell Physiol 2018; 233(6): 4563-77.
21. Farashi S, Harteveld CL. Molecular basis of alpha-thalassemia. Blood Cell Mol Dis 2018; 70: 43-53.
22. Langer AL. Beta-Thalassemia. 1993:
23. Mettananda S, Gibbons RJ, Higgs DR. alpha-Globin as a molecular target in the treatment of beta-thalassemia. Blood 2015; 125(24): 3694-701.
24. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001; 2(4): 245-55.
Sva prava zadržana (c) 2024 Heng Wang, Hai Huang, Yaping Chen, Dan Xie, Bangquan An, Shengwen Huang
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.